Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
December 23, 2021 07:27 AM EST
Pharma
FDA+

It's a year late, but No­var­tis has fi­nal­ly steered in­clisir­an to FDA ap­proval. Will it sell?

Amber Tong

Senior Editor

The cen­ter­piece of No­var­tis’s $9.7 bil­lion buy­out of the Med­i­cines Com­pa­ny can fi­nal­ly go to mar­ket.

Brand­ed Leqvio, the small in­ter­fer­ing RNA ther­a­py long …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times